Compare Quest Diagnostics Inc (DGX) vs Tesla, Inc. (TSLA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs Tesla, Inc. — how do they compare? Quest Diagnostics Inc trades at $204.68 (market cap $22.80B), while Tesla, Inc. trades at $396.06 (market cap $1.49T). The key difference: Tesla, Inc. is far larger — about 65.4× Quest Diagnostics Inc's market cap, and Quest Diagnostics Inc pays a 1.67% dividend while Tesla, Inc. pays none. Which is the better fit depends on your goals.
| DGX | TSLA | |
|---|---|---|
Market Cap | $22.80B | $1.49T |
Sector | Health | Consumer Cyclical |
52-Week High | $216.02 | $489.88 |
52-Week Low | $166.42 | $302.63 |
Enterprise Value | $28.82B | $1.46T |
Dividend Yield | 1.67% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $207.35, showing minimal daily movement with a slight decline of 0.04%. The stock maintains a bullish technical stance with recent earnings beats and analyst consensus pointing to upside potential. Recent developments include New York State approval for Haystack MRD testing and strong momentum across diagnostic channels. Revenue growth accelerated to $11.04 billion in 2025 with consistent profitability margins around 9%.
DGX presents a balanced investment case with 38% analyst buy ratings and a $227.75 price target suggesting 10% upside. The company demonstrates steady revenue growth and operational efficiency, though elevated debt levels and policy risks require monitoring. Second quarter earnings on July 23, 2026, will be crucial for validating current momentum and growth trajectory.
Tesla (TSLA) trades at $396.87, up 0.53% with mixed technical signals showing bearish moving averages but neutral oscillators. The company faces valuation challenges with a P/E ratio of 363.47 and declining profit margins, though recent earnings beat expectations in Q1 2026. Positive developments include regulatory approval for self-driving software in Europe and strong growth in German registrations.
Tesla's outlook balances innovation potential against execution risks. The stock offers exposure to autonomous driving leadership and energy growth, but faces intense EV competition and margin pressure. Analyst consensus price target of $409.26 suggests modest upside, though institutional sentiment remains divided with 39.5% buy ratings versus 18.5% sell recommendations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About Tesla, Inc.
Tesla Inc. designs, manufactures, and sells high-performance electric vehicles and electric vehicle powertrain components. The Company owns its sales and service network and sells electric power train components to other automobile manufacturers. Tesla serves customers worldwide.
Read more on TSLA →
